RVNC: Revance Therapeutics Inc Price to Sales

Corporate company logo of Revance Therapeutics Inc. (RVNC)

Revance Therapeutics (RVNC) has established a closed B2B ecosystem around Daxxify, securing clinics through exclusive supply agreements. The current P/S multiple reflects the market valuation of sales, where the 1.50 mark indicates the business value level. The company generates revenue through the sale of fillers and botulinum toxins. Growth prospects are based on the expansion of the drugs' therapeutic properties and successful clinical trials.

Revance Therapeutics - RVNC P/S Multiple (period 07/04/2022 - 02/16/2025)

Analytical breakdowns for revance.com (RVNC)

- share price and consensus valuation forecast:
Price Performance Chart Revance Therapeutics, Inc.|RVNC - Analyst Consensus Forecast
- market capitalization information:
Market Value Revance Therapeutics, Inc.|RVNC - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Net Assets per Single Share Revance Therapeutics|RVNC - Book Capitalization|Market Capitalization to Book Value Ratio revance.com|RVNC - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Ratio Revance Therapeutics|RVNC - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Revance Therapeutics|RVNC - Company Aggregate Debts|Debts to Book Value Revance Therapeutics, Inc.|RVNC - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Revance Therapeutics|Intermediate Liquidity Ratio revance.com
- financial results and valuation multiples details:
RVNC - Net Profit|Expected Net Income Revance Therapeutics|RVNC - P/E Multiple|Projected Price to Earnings Ratio Revance Therapeutics Inc|RVNC - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Revance Therapeutics Inc|RVNC - Operating profit EBITDA|Net earnings per share (EPS TTM) Revance Therapeutics|RVNC - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months revance.com|RVNC - Earnings growth in current year|Expected net earnings per share growth next year Revance Therapeutics
- issuer revenue and sales details:
RVNC - Company Sales|Projected Sales Volume Revance Therapeutics, Inc|RVNC - Market Cap to Revenue|Price to Expected Revenue Ratio Revance Therapeutics Inc
General company analysis:RVNC - Revance Therapeutics, Inc
Manufactured products of Revance Therapeutics

Revance Therapeutics (RVNC) maintains production independence through its own automated plant in California, which allows investors to track the monetization efficiency of these manufacturing capacities via P/S ratio history. This multiple compares market capitalization to annual revenue, determining the cost of each unit of sales and helping investors distinguish fundamental business growth from speculative asset price overheating.

Who Revance Therapeutics competes with

P/S Multiple Krystal Biotech Inc (KRYS)|Price-to-Revenue Ratio Apogee Therapeutics, Inc. APGE|Market Capitalization-to-Revenue Ratio ARQT|VCEL - Price-to-Revenue Ratio|ORKA - P/S Multiple|SMTI: P/S Multiple|DBV Technologies S.A. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Solesence|Market Cap to Revenue Ratio DERM (Journey Medical)|Market Cap to Revenue FBRX (Forte Biosciences, Inc.)|EMPG (Empro Group Inc) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Sol-Gel Technologies Ltd. SLGL|Market Capitalization-to-Revenue Ratio AXIL|MDCX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio VRCA (Verrica Pharmaceuticals Inc.)|Hoth (HOTH) - Price-to-Revenue Ratio|Price to Sales Biofrontera Inc (BFRI)|VYNE (VYNE Therapeutics Inc) - P/S Multiple|P/S Multiple sonomapharma.com|Price-to-Revenue Ratio Quoin Pharmaceuticals Ltd (QNRX)|Price-to-Revenue Coefficient Azitra Corp|Price-to-Revenue Ratio Dermata Therapeutics DRMA|Market Capitalization-to-Revenue Ratio ELAB